Compare · CRM vs SNCE
CRM vs SNCE
Side-by-side comparison of Salesforce Inc. (CRM) and Science 37 Holdings Inc. (SNCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRM and SNCE operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRM is the larger of the two at $168.46B, about 182.9x SNCE ($921.1M).
- CRM has hit the wire 18 times in the past 4 weeks while SNCE has been quiet.
- CRM has more recent analyst coverage (25 ratings vs 5 for SNCE).
- Company
- Salesforce Inc.
- Science 37 Holdings Inc.
- Price
- -
- -
- Market cap
- $168.46B
- $921.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- 2020
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 5
Salesforce Inc.
salesforce.com, inc. develops enterprise cloud computing solutions with a focus on customer relationship management worldwide. The company offers Sales Cloud to store data, monitor leads and progress, forecast opportunities, and gain insights through analytics and relationship intelligence, as well as deliver quotes, contracts, and invoices. It also provides Service Cloud, which enables companies to deliver personalized customer service and support, as well as a field service solution that enables companies to connect agents, dispatchers, and mobile employees through a centralized platform, which helps to schedule and dispatch work, and track and manage jobs in real-time. In addition, the company offers Marketing Cloud to plan, personalize, and optimize one-to-one customer marketing interactions; and Commerce Cloud, which enables companies to enhance engagement, conversion, revenue, and loyalty from their customers. Further, it provides Customer 360 Platform that offers no-code to pro-code Platform-as-a-Service tools for building, securing, integrating, and managing the business apps; MuleSoft Anypoint Platform enables customers to connect any system, application, data, or device; Quip collaboration platform, which combines documents, spreadsheets, apps, and chat with live CRM data; and Tableau and Einstein Analytics, provides analytical technology to customers. Additionally, the company offers various solutions for financial services, healthcare and life sciences, manufacturing, consumer goods, government, and philanthropy. The company also provides professional services and education services, including instructor-led and online courses; and support and adoption programs. It provides its services through direct sales; and consulting firms, systems integrators, and other partners. Salesforce and Siemens has a strategic partnership. The company was founded in 1999 and is headquartered in San Francisco, California.
Latest CRM
- President and COO Milano Miguel converted options into 1,662 shares and covered exercise/tax liability with 678 shares, increasing direct ownership by 3% to 38,754 units (SEC Form 4)
- President and CLO Niles Sabastian converted options into 1,662 shares and covered exercise/tax liability with 920 shares, increasing direct ownership by 3% to 27,037 units (SEC Form 4)
- Director Sachin J. Mehra converted options into 441 shares, increasing direct ownership by 9% to 5,406 units (SEC Form 4)
- Director Munoz Oscar converted options into 441 shares, increasing direct ownership by 3% to 13,990 units (SEC Form 4)
- Director Kroes Neelie converted options into 441 shares and covered exercise/tax liability with 67 shares, increasing direct ownership by 5% to 8,490 units (SEC Form 4)
- Director Alber Laura converted options into 441 shares, increasing direct ownership by 4% to 10,413 units (SEC Form 4)
- Director Roos John Victor converted options into 441 shares, increasing direct ownership by 3% to 17,289 units (SEC Form 4)
- Director Kirk David Blair converted options into 441 shares, increasing direct ownership by 3% to 14,572 units (SEC Form 4)
- Director Conway Craig converted options into 441 shares, increasing direct ownership by 5% to 9,937 units (SEC Form 4)
- Director Donald Arnold W converted options into 441 shares (SEC Form 4)
Latest SNCE
- Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
- Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
- Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
- Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
- Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
- Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
- Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
- Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance